TYROSINE KINASE INHIBITORS AND INTERFERON
The use of interferon-a (INF) in chronic myeloid leukemia, when it started in the 80s, was considered as a breakthrough in the therapy of this disease; INF administered alone or in combination with aracytine was the standard choice for treatment for Chronic Myeloid Leukemia (CML) patients unfi...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2014-01-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/index.php/mjhid/article/view/1359 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846095724583845888 |
|---|---|
| author | Maria Dimou Panagiotis Panagiotidis |
| author_facet | Maria Dimou Panagiotis Panagiotidis |
| author_sort | Maria Dimou |
| collection | DOAJ |
| description | The use of interferon-a (INF) in chronic myeloid leukemia, when it started in the 80s, was considered as a breakthrough in the therapy of this disease; INF administered alone or in combination with aracytine was the standard choice for treatment for Chronic Myeloid Leukemia (CML) patients unfit for bone marrow transplantation. With the appearance of the first Tyrosine Kinase Inhibitor (TKI) (imatinib) and based on the results of the pivotal IRIS trial, imatinib monotherapy was the new treatment of choice for CML, according to the ELN recommendations. The possibility of combining INF with imatinib, for obtaining better therapeutic responses in CML patients has been already tested and reported. The current challenge is the combined use of second generation TKIs with pegylated –IFN, in order to minimize failures to therapy and increase the number of CML patients with deep molecular responses, who may be able to discontinue lifelong treatment. |
| format | Article |
| id | doaj-art-589bd002c8f144d4b7e97ec577b84c25 |
| institution | Kabale University |
| issn | 2035-3006 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-589bd002c8f144d4b7e97ec577b84c252025-01-02T09:42:33ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062014-01-0161e2014006e201400610.4084/mjhid.2014.0061119TYROSINE KINASE INHIBITORS AND INTERFERONMaria Dimou0Panagiotis Panagiotidis11st Department of Propaedutic Medicine, Division of Hematology, University of Athens, Greece1st Department of Propaedutic Medicine, Division of Hematology, University of Athens, GreeceThe use of interferon-a (INF) in chronic myeloid leukemia, when it started in the 80s, was considered as a breakthrough in the therapy of this disease; INF administered alone or in combination with aracytine was the standard choice for treatment for Chronic Myeloid Leukemia (CML) patients unfit for bone marrow transplantation. With the appearance of the first Tyrosine Kinase Inhibitor (TKI) (imatinib) and based on the results of the pivotal IRIS trial, imatinib monotherapy was the new treatment of choice for CML, according to the ELN recommendations. The possibility of combining INF with imatinib, for obtaining better therapeutic responses in CML patients has been already tested and reported. The current challenge is the combined use of second generation TKIs with pegylated –IFN, in order to minimize failures to therapy and increase the number of CML patients with deep molecular responses, who may be able to discontinue lifelong treatment.http://www.mjhid.org/index.php/mjhid/article/view/1359tyrosine kinase inhibitorsinterferon-alphachronic myeloid leukemiapegylated interferon alphatreatment discontinuation |
| spellingShingle | Maria Dimou Panagiotis Panagiotidis TYROSINE KINASE INHIBITORS AND INTERFERON Mediterranean Journal of Hematology and Infectious Diseases tyrosine kinase inhibitors interferon-alpha chronic myeloid leukemia pegylated interferon alpha treatment discontinuation |
| title | TYROSINE KINASE INHIBITORS AND INTERFERON |
| title_full | TYROSINE KINASE INHIBITORS AND INTERFERON |
| title_fullStr | TYROSINE KINASE INHIBITORS AND INTERFERON |
| title_full_unstemmed | TYROSINE KINASE INHIBITORS AND INTERFERON |
| title_short | TYROSINE KINASE INHIBITORS AND INTERFERON |
| title_sort | tyrosine kinase inhibitors and interferon |
| topic | tyrosine kinase inhibitors interferon-alpha chronic myeloid leukemia pegylated interferon alpha treatment discontinuation |
| url | http://www.mjhid.org/index.php/mjhid/article/view/1359 |
| work_keys_str_mv | AT mariadimou tyrosinekinaseinhibitorsandinterferon AT panagiotispanagiotidis tyrosinekinaseinhibitorsandinterferon |